According to a recent study from Health Strategies Insights by EVERSANA, 89% of U.S. physicians disagree with Germany’s determinations of the clinical benefit of innovative diabetes medicines.
Learn more about our Market Access products & capabilities!
Contact us with your questions and data needs, and an expert will follow up shortly.
NAVLIN Insights gives you an advanced set of capabilities, frameworks, and methods. These are all derived from a robust stakeholder panel, providing critical answers to your specific payer marketing and market access questions. Learn…